DAEJU Meditech Engineering, established in 2006 and incorporated in 2015, has been manufacturing and exporting advanced medical and aesthetic devices for over 18 years. With certifications such as European CE, US FDA, Brazilian ANVISA, and many others, the company has built trust globally, supplying products to more than 40 countries. Leveraging years of experience and proven reliability, DAEJU is steadily expanding into the domestic medical device market while committing to continuous R&D investments to meet customer needs and lead the globalization of K-medical devices.
In 2019, DAEJU recorded sales of approximately 3 billion KRW, but the COVID-19 pandemic brought challenges, causing a temporary decline. However, the company rebounded, achieving over 5 billion KRW in 2023—double its 2019 sales—and maintained steady growth in 2024. DAEJU’s consistent growth trajectory demonstrates its success in overcoming global challenges and expanding its market presence.
At KIMES 2025, DAEJU Meditech Engineering will present the NOABLE LASER, a cutting-edge 1450nm diode laser system designed for acne treatment. This device delivers targeted heat to sebaceous glands, effectively reducing sebum production and improving acne conditions. It offers two operation modes—stamping and toning—with customizable spot sizes (4mm, 6mm, 8mm, and 10mm) selected via the user interface without the need for lens changes. The stamping mode focuses on targeted areas for localized treatment, while the toning mode addresses overall sebum reduction and acne improvement across the entire face. The DCD Cooling system minimizes discomfort during procedures, enhancing patient comfort. Key benefits include effective acne treatment, reduced treatment times, lower acne recurrence rates, skin regeneration, and reduced inflammation and sebum production.
DAEJU Meditech Engineering views KIMES 2025 as an opportunity to strengthen its global network by connecting with buyers from various regions. The company aims to expand exports, focusing on Asia, the Middle East, and Africa. Asia-Pacific, the second-largest aesthetic laser market globally after North America, represents a key target market for the company. Furthermore, DAEJU seeks to establish strong partnerships in the Middle East and Africa to increase its market share and revenue in these regions.
Having recently obtained US FDA certification for one of its products, DAEJU is actively pursuing regulatory approvals in several other countries, further paving the way for international expansion. Looking ahead, the company plans to incorporate AI-driven solutions into its medical devices, reinforcing its commitment to innovation and its goal of global leadership in K-medical technology. Meanwhile, DAEJU Meditech Engineering's participation at KIMES 2025, held from March 20 to 23 at COEX in Seoul, marks another step in its journey toward global recognition.